Pemvidutide

Overview

Pemvidutide is a dual GLP-1 and glucagon receptor agonist investigated in metabolic dysfunction-associated steatohepatitis and related metabolic outcomes. Liver histology, noninvasive markers, weight, and cardiovascular risk factors are distinct endpoints.

Evidence quality

WPF’s atlas includes reports and abstracts from the phase 2b IMPACT study and a meta-analysis of randomized trials. Conference abstracts and top-line reports can flag emerging results, but require comparison with complete methods and peer-reviewed outcome data before firm conclusions.

Safety concerns

This Directory entry has no published source-linked citations or jurisdiction-specific regulatory records. A change in a surrogate marker or exploratory analysis does not by itself establish clinical benefit, durability, or an approved indication.

Citations as of this version

• Efficacy and safety of pemvidutide in metabolic dysfunction-associated steatohepatitis: a GRADE-assessed meta-analysis of randomized controlled trials. (2026)
• The dual GLP-1-glucagon agonist pemvidutide in MASH: a phase 2b trial. (2025)
• Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study. (2025)
• Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study. (2025)
• Safety and efficacy of 24 weeks of pemvidutide in metabolic dysfunction-associated steatotic liver disease: A randomized, controlled clinical trial. (2025)

Regulatory status as of this version

• United States — FDA: not_approved
• European Union — EMA: not_approved